WO2012091425A3 - 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물 - Google Patents

4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물 Download PDF

Info

Publication number
WO2012091425A3
WO2012091425A3 PCT/KR2011/010179 KR2011010179W WO2012091425A3 WO 2012091425 A3 WO2012091425 A3 WO 2012091425A3 KR 2011010179 W KR2011010179 W KR 2011010179W WO 2012091425 A3 WO2012091425 A3 WO 2012091425A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxytamoxifen
analog
composition containing
preventing
metabolic syndrome
Prior art date
Application number
PCT/KR2011/010179
Other languages
English (en)
French (fr)
Other versions
WO2012091425A2 (ko
Inventor
최흥식
박승범
이철호
구승회
Original Assignee
전남대학교산학협력단
한국생명공학연구원
서울대학교산학협력단
성균관대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020100135875A external-priority patent/KR101311534B1/ko
Priority claimed from KR1020110054178A external-priority patent/KR101304536B1/ko
Application filed by 전남대학교산학협력단, 한국생명공학연구원, 서울대학교산학협력단, 성균관대학교산학협력단 filed Critical 전남대학교산학협력단
Publication of WO2012091425A2 publication Critical patent/WO2012091425A2/ko
Publication of WO2012091425A3 publication Critical patent/WO2012091425A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 대사증후군 관련 질환의 예방 또는 치료용 약제학적 조성물, 상기 조성물을 이용한 대사증후군 관련 질환의 예방 또는 치료 방법, 4-하이드록시 타목시펜 유사체를 포함하는 대사증후군 관련 질환의 예방 또는 개선용 식품 조성물, 4-하이드록시 타목시펜 유사체를 포함하는 혈액 내의 콜레스테롤 감소용 조성물, 및 4-하이드록시 타목시펜 유사체를 포함하는 간 또는 혈액에서의 글루코스 수치 감소용 조성물에 관한 것이다.
PCT/KR2011/010179 2010-12-27 2011-12-27 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물 WO2012091425A2 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2010-0135875 2010-12-27
KR1020100135875A KR101311534B1 (ko) 2010-12-27 2010-12-27 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 당뇨병 치료 또는 예방용 조성물
KR10-2011-0054178 2011-06-03
KR1020110054178A KR101304536B1 (ko) 2011-06-03 2011-06-03 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 간질환의 치료 또는 예방용 조성물

Publications (2)

Publication Number Publication Date
WO2012091425A2 WO2012091425A2 (ko) 2012-07-05
WO2012091425A3 true WO2012091425A3 (ko) 2012-12-06

Family

ID=46383698

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/010179 WO2012091425A2 (ko) 2010-12-27 2011-12-27 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물

Country Status (1)

Country Link
WO (1) WO2012091425A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101481007B1 (ko) 2012-07-19 2015-01-14 전남대학교산학협력단 심장 비대 억제 조성물 및 이를 포함하는 심장비대증 치료제
CN104429132A (zh) 2012-08-17 2015-03-18 英特尔公司 多信道功率控制

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970705999A (ko) * 1994-09-20 1997-11-03 스트링거 피터 지 타목시펜 및 타목시펜 유사체의 자궁향성 효과를 최소화시키는 방법 (a method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs)
US6555530B1 (en) * 1999-01-18 2003-04-29 Novo Nordisk A/S Use of estrogens and delta-gonadien-21-Ol-3,20-diones for treating insulin dependent and non-insulin dependent diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970705999A (ko) * 1994-09-20 1997-11-03 스트링거 피터 지 타목시펜 및 타목시펜 유사체의 자궁향성 효과를 최소화시키는 방법 (a method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs)
US6555530B1 (en) * 1999-01-18 2003-04-29 Novo Nordisk A/S Use of estrogens and delta-gonadien-21-Ol-3,20-diones for treating insulin dependent and non-insulin dependent diabetes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SARAH J. DUELLMAN ET AL.: "A novel steroidal inhibitor of estrogen-related recept or a (ERR a).", BIOCHEMICAL PHARMACOLOGY., vol. 80, no. 6, 31 March 2010 (2010-03-31), pages 819 - 826 *
YUAN-BIN XIE ET AL.: "Transcriptional Corepressor SMILE Recruits SIRT1 to Inhibit Nuclear REceptor Estrogen Receptor-related Receptor y Transactivation.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 284, no. 42, 16 October 2009 (2009-10-16), pages 28762 - 28774 *

Also Published As

Publication number Publication date
WO2012091425A2 (ko) 2012-07-05

Similar Documents

Publication Publication Date Title
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
EP2727605A4 (en) ANALOGUE OF POLYETHYLENE GLYCOL EXENDIN-4 OR A DERIVATIVE THEREOF, ITS PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES, CONTAINING THE SAME AS ACTIVE INGREDIENT
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
GEP201706719B (en) Pirfenidone treatment for patients with atypical liver function
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
IL226386A0 (en) Medical treatment for metabolic syndrome, type 2 diabetes, obesity or pre-diabetes
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2011049327A3 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
PH12014502802A1 (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
PH12015500653B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
WO2013019091A3 (en) A COMPOUND FOR INHIBITING 11β-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
WO2012024583A3 (en) Oxysterol compounds
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2012085249A3 (en) Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
AU2012207301A8 (en) Apolipoprotein AIV as an antidiabetic peptide
WO2008092219A3 (en) Pharmaceutical composition comprising tramadol and ketoprofen
MX2014001823A (es) Combinaciones de corroles y estatinas.
WO2012091425A3 (ko) 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물
EP2875823A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHIES CONTAINING HENOSIS STAPF EXTRACT FROM VAR. MUNRO OF PHYLLOSTACHYS NIGRA AS ACTIVE INGREDIENT
EP2476420B8 (en) Pharmaceutical composition having antimicrobial and fast-healing activity for external administration, process for preparing same
WO2011141113A3 (de) Kombination aus vitamin k und nikotinamid
WO2014018763A3 (en) Method of treating type i diabetes using apolipoprotein aiv

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11853308

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11853308

Country of ref document: EP

Kind code of ref document: A2